| Dr. Ling brings with her more than 25 years of experience in biologics development, including cell and gene therapies, and joins Catalent from Rocket Pharma, where she held the role of Head of Manufacturing, Science and Technology. Prior to Rocket, Dr. Ling worked at Merck & Co. (MSD), where she led biologics CMC development and supported regulatory filing. Prior to Merck, she was at Schering-Plough Corp., where she worked on adenoviral gene therapy development and manufacturing prior to transition to biologics. She earned her Bachelor of Science degree in Biochemistry from the University of California, Los Angeles, and her Doctorate degree in Pharmacology from the Rutgers University. Dr. Ling also completed her post-doctoral research fellowship at the Albert Einstein College of Medicine, New York. |
